## Abstract The influence of __p53__ mutations on the response to ionizing radiation and survival was retrospectively evaluated in patients treated with preoperative radiotherapy for rectal carcinoma. From 1989 to 1991, 86 rectal cancer patients treated by preoperative radiotherapy were included in
Prognostic markers in rectal carcinoma
β Scribed by J. Milburn Jessup; Massimo Loda
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 63 KB
- Volume
- 15
- Category
- Article
- ISSN
- 8756-0437
No coin nor oath required. For personal study only.
β¦ Synopsis
Guidelines from two major organizations have recently supported the use of only the serological marker carcinoembryonic antigen (CEA) for the prognostication and monitoring of patients with colorectal carcinoma. However, in view of the exciting advances made recently in elucidating the molecular and cellular biology of adenocarcinoma of the rectum, the molecules that transform the well-ordered normal rectal epithelium into an invasive adenocarcinoma may yield information about the ultimate behavior of that cancer. Consequently, assessing the expression of molecules within a primary cancer may predict the probability of regional and distant metastasis, response to therapy, and outcome. This review analyzes the current state of intratumoral expression of several molecular markers for the management of rectal cancer and evaluates their potential for defining which patients may undergo rectal sphincter preservation and need adjuvant therapy.
π SIMILAR VOLUMES
## BACKGROUND. The prognosis for patients with renal cell carcinoma depends mainly on pathological stage and grade of the tumor at the time of surgery. Cellular proliferation may prove to be another measure for predicting biologic aggressiveness and, therefore, the prognosis. ## METHODS. The au
## Abstract ## Background We evaluated the predictive significance of 14 reported markers using immunohistochemical study in nasopharyngeal carcinoma. ## Methods Immunohistochemical stainings were done in 38 patients for Met, cyclooxygenaseβ2 (COXβ2), nm23βH1, epidermal growth factor receptor (E